[
    [
        {
            "time": "",
            "original_text": "粤开策略：明年1月A股有望实现开门红 重点关註三条主线投资机会",
            "features": {
                "keywords": [
                    "开门红",
                    "A股",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "粤开策略：明年1月A股有望实现开门红 重点关註三条主线投资机会",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司目前未研发非奈利酮",
            "features": {
                "keywords": [
                    "华东医药",
                    "非奈利酮",
                    "研发"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司目前未研发非奈利酮",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司目前未有安宫牛黄丸产品，亦暂无研发该品种的计划",
            "features": {
                "keywords": [
                    "华东医药",
                    "安宫牛黄丸",
                    "研发计划"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司目前未有安宫牛黄丸产品，亦暂无研发该品种的计划",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "老字号也玩跨界，云南白药拟增资5亿元入局医美，明年将开8家门诊",
            "features": {
                "keywords": [
                    "云南白药",
                    "医美",
                    "增资",
                    "跨界"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "老字号也玩跨界，云南白药拟增资5亿元入局医美，明年将开8家门诊",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "进军医美！千亿中药龙头5亿增资子公司，推进医美产业链布局…这些药企也已布局，赛道前景如何？",
            "features": {
                "keywords": [
                    "中药龙头",
                    "医美",
                    "增资",
                    "产业链"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "进军医美！千亿中药龙头5亿增资子公司，推进医美产业链布局…这些药企也已布局，赛道前景如何？",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]